BACKGROUND Postoperative management of clinically nonfunctioning pituitary adenomas (NFPA) presents difficult challenges. There are no good serum markers for presence or growth of the tumour, medical treatment is not effective and radiotherapy carries the risk of significant side-effects.
PATIENTS One hundred and twenty-two patients (78M / 45F) operated on at our institution since 1989 and with a minimal follow-up of 1 year comprised the study group.
MEASUREMENTS Tumour size and characteristics were determined by MRI using a modification of Hardy's and Wilson's classifications. Maximal tumour height was also recorded and the information was routinely stored in a computerized database.
RESULTS Mean (± ± ± ± SD) follow-up was 51 ± ± ± ± 31 months. Fourteen patients received postoperative radiation therapy. Subsequent tumour growth was observed in five of them, reduction in tumour size in four and no size changes in five. One hundred and eight patients did not receive postoperative radiation. Tumour enlargement occurred in 41 of 78 and in six of 30 patients with and without residual tumour after operation ( P = 0·0024). The presence of cavernous sinus invasion before surgery [ P = 0·02, odds ratio (OR) 2·72; confidence interval (CI) 1·1-6·43] and the extent of suprasellar extension in the postoperative tumour remnant ( P = 0·0054 for presence of stage A, OR 4·4; 95% CI 1·5-12·5; and P = 0·012 for presence of stages B or C, OR 16·2; CI 1·8 -144) were strong independent predictors of tumour enlargement. CONCLUSION Our data may ease the selection of patients in whom radiation therapy is likely to be necessary for tumour control, and confirms that close postoperative follow-up is an adequate primary approach in low-risk patients.
The treatment and follow up of clinically nonfunctioning pituitary adenomas (NFPA) remain a difficult challenge for the clinician. In the absence of defined syndromes of hormonal hypersecretion, patients harbouring NFPA often present with symptoms arising from the effect of advanced tumour expansion and invasion to neighbouring structures. At this stage, tumour burden is such that surgery is almost never curative.
The aftermath of this first therapeutic procedure is not devoid of dilemmas (Plowman, 1999) . In the absence of good serum markers for residual tumour presence (Greenman et al ., 1998) , decision on the need for further intervention relies mainly on sequential postoperative anatomical imaging. From our present understanding of tumour biological behaviour, residual cells retain their inherent ability to proliferate, unless additional measures are applied. On the other hand, many of these tumours grow very slowly, and hence may not reach a large enough volume to impair health within the patient's lifetime (Grigsby et al ., 1989; Laws & Thapar, 1995) . Preventive postoperative treatment is thus frequently withheld (Lillehei et al ., 1998) , especially as radiation, the only currently available treatment, carries the risk of significant side-effects (Hansen & Molitch, 1998) .
The purpose of this study was to investigate the natural history and biological behaviour of NFPA after transsphenoidal surgery. A special effort was made to identify tumour/patient characteristics indicative of a more aggressive course, which could assist in the clinical decision-making process.
Patients and methods
Between 1989 and 2000, 238 patients were operated for NFPA at the Neurosurgery Department of the Tel Aviv-Sourasky Medical Center, Tel Aviv, a referral centre for pituitary surgery in Israel, by one neurosurgeon (GO). All 122 patients who continued their treatment at our centre and had a minimal follow-up time of 12 months were included in this analysis.
These patients were studied prospectively using a uniform protocol for clinical management. Magnetic resonance imaging (MRI) studies were performed in all patients before, 3, 6 and 12 months after surgery, and yearly thereafter for the first 5 years. Subsequently, imaging was performed once every 2 years or as clinically indicated. For the present analysis, the date of the last available MRI was recorded as the last visit.
Until 1992, some patients were still referred to postoperative radiation therapy. From then on, patients were referred to radiotherapy only in the event of tumour regrowth or remnant enlargement.
Tumour size and growth characteristics were determined by MRI and direct surgical inspection, using a modification of Wilson's and Hardy's classifications, developed by one of us (GO; Ouaknine et al ., 1997) . Briefly, grades I, II, III and IV indicate microadenoma, noninvasive macroadenoma, invasive microadenoma and invasive macroadenoma, respectively. Stages A, B and C indicate increasing degrees of suprasellar extension, as follows:
• Stage A -the adenoma extends just above the clinoid line and bulges into the suprasellar cistern. The tumour may reach but not displace the optic chiasm and does not deform the third ventricle.
• Stage B -the adenoma occupies the suprasellar cistern, elevates the chiasm and obliterates the anterior recess of the third ventricle.
• Stage C -the tumour elevates the floor of the third ventricle, may reach the foramen of Monro and extend further upwards.
Stages a, b and c indicate increasing extent of infrasellar extension:
• Stage a -tumour induced bulging of the sellar floor into the sphenoid sinus.
• Stage b -extension of the adenoma through the sellar floor and the sphenoid sinus until the sphenoid floor.
• Stage c -extension of the tumour all the way through the sphenoid sinus, destroying the sphenoid floor with possible invasion of the nasopharynx.
• Stage D -denotes parasellar extension outside the sella turcica towards the cranial fossae.
• Stage E -indicate invasion of the cavernous sinus:
E1 -extension between the loops of the carotid artery. E2 -encasement of at least one loop of the carotid artery. E3 -extension outside the cavernous sinus (outside the lateral or superior wall of the cavernous sinus or along the petroclival ligament). Measurements of tumour size were performed in the coronal cut of MRI, optimally showing the infundibulum and the optic chiasm. Height at midline and maximal tumour height in the case of an excentric mass were recorded.
Patients with postoperative MRI demonstrating a normal pituitary gland and no evidence of residual tumour were followed for detection of a possible recurrence. Patients with postoperative MRI demonstrating residual tumour that did not require immediate re-treatment, were followed for detection of possible remnant enlargement.
Recurrence or remnant enlargement were considered together as common end points for analysis of association with other tumoural parameters.
Statistical analysis
The association between tumour characteristics and changes in tumour size were examined using the χ 2 or the Fisher test for categorical variables. The rank-sum (Mann-Whitney) test was used for between-group comparisons for numerical variables.
Results are expressed as the mean ± SD. All variables that were associated with tumour enlargement with a significance level of < 0·1 were included in the multiple logistic regression analysis. This model was utilized to assess the independent association of the different parameters with tumour enlargement. Several variable selection methods were used to determine the final model. The time to detection of tumour enlargement and the median recurrence-free survival time were estimated using the KaplanMeier method.
Results
One hundred and twenty-two patients (78M/44F) with a mean age of 55·3 ± 14·4 years (range 17-80 years) were followed for 51 ± 31 months (range 12-133 months). Clinical presentation was related to mass effect of the tumour, except for 10% of patients in whom the diagnosis of pituitary adenoma was an incidental finding. Twenty-nine per cent of patients presented with headaches, visual complaints led to the diagnosis in 18% of patients and symptoms due to compression of cranial nerves (diplopia, ptosis) were present in 14% of patients. Symptoms related to hypopituitarism led to the diagnosis in 34% of patients, and in almost half of them, complaints were secondary to hypogonadism (some patients presented with more than one complaint).
All tumours were macroadenomas. Table 1 shows tumour classification by grade and stage before and after surgery in this cohort. Cavernous sinus invasion was present in 48% of tumours preoperatively. Table 2 depicts the impact of surgery on pituitary function and vision fields.
Irradiated patients were analysed separately.
Patients who did not receive radiation therapy
One hundred and eight patients were not treated with radiation after surgery. Growth of tumour remnant was observed in 47 of them (43%), whereas in 61 (57%) no changes were detected by MRI. Spontaneous tumour shrinkage did not occur in this group. There was no difference in sex or age between patients who experienced postoperative tumour enlargement and those who did not. Similarly, presence of hypopituitarism or visual field defects were not associated with specific outcomes after surgery.
Relationship between preoperative tumour characteristics and postoperative tumour growth
Thirty-four out of 65 (52·3%) grade IV invasive macroadenomas showed postoperative growth, whereas only 30% (13/43) of grade II enclosed macroadenomas had this behaviour after surgery ( P < 0·029; Fig. 1 ). Tumours with more pronounced suprasellar extension had a higher incidence of subsequent enlargement (stage A, 2/12; stage B, 28/73; stage C, 17/23; P < 0·0001; Fig. 2a) . Similarly, tumours with more advanced infrasellar extension had a higher rate of subsequent enlargement (stage 0, 1/6; stage a, 12/35; stage b, 22/ 52; stage c, 12/15; P < 0·0078; Fig. 2b ). Tumours with cavernous sinuses invasion before surgery tended to have residual tumour growth after surgery ( P = 0·056). 
Relationship between the presence of a radiologicaly 'normal gland' after surgery and tumour recurrence
In 30 patients 'gross total removal' of the tumour was achieved, whereas in 78 subjects a significant residual mass was detected on MRI performed 3 months after surgery. Tumour enlargement occurred in 41 of 78 patients with residual tumour after operation (52·5%) and recurrence occurred in six of 30 (20%) patients in whom a 'normal gland' (NG) was present in the postoperative MRI ( P = 0·0024; Fig. 3) . Twenty of 44 patients with grade II tumours, but only 11 of 78 patients with grade IV tumours, had NG on MRI 3 months after surgery ( P < 0·0001). Increasing degrees of supra-( P < 0·009), infra-( P < 0·0001), para-( P < 0·0018) and extrasellar ( P = 0·03) extension before surgery accordingly reduced the probability of having a NG on imaging after surgery. Multiple logistic regression analysis defined the presence of preoperative invasion of cavernous sinus as the strongest independent negative predictor of NG after surgery [ P = 0·0067, odds ratio (OR) 0·36; confidence interval (CI) 0·173 -0·754].
Relationship between postoperative tumour characteristics and subsequent tumour growth
Tumours with a higher stage of suprasellar extension after surgery had an increased incidence of subsequent enlargement (stage 0, 26/78, 33·3%; stage A, 14/22, 63·3%; stage B, 6/7, 85·7%; stage C, 1/1, 100%; P = 0·0012; Fig. 4) . Similarly, patients with increasing degrees of infrasellar extension after surgery had a higher rate of subsequent tumour enlargement than tumours without infrasellar involvement ( P < 0·0001). Increasing degrees of invasion to the cavernous sinuses was also positively correlated to the propensity for tumour growth after surgery: tumour growth was observed after surgery in five of five patients with E3 tumours, in six of 13 (46·2%) patients with E2 tumours, in 10/ 21 (47·6%) patients with E1 tumours and in 26/69 (37·7%) of patients without invasion to cavernous sinus ( P < 0·045; Fig. 5 ).
Multiple logistic regression analysis
To assess the independent influence of the different parameters, variables found to be associated with postoperative enlargement of the residual mass were entered into a multiple logistic regression analysis model. Only nonirradiated patients were included in this analysis. Parameters defining grade, supra-, infra-and parasellar extension before and after surgery were entered into this model. The presence and degree of postoperative suprasellar extension was independently associated with subsequent growth ( P = 0·0054 for presence of stage A, OR 4·4; 95% CI 1·5-12·5; P = 0·012 for presence of stage B or C, OR 16·2; CI 1·8-144). The presence of invasion to cavernous sinus before surgery was also independently associated with tumour growth/recurrence after surgery ( P = 0·02, OR 2·72; CI 1·1-6·43). In this model, the association of predicted probabilities and observed response had a c -value of 0·719, meaning that it correctly predicts about 72% of the observed end-points.
Relapse-free (tumour control) survival
Tumour enlargement was detected 6 -96 months after surgery (mean 31 ± 18 months) in 47 patients. Routine MRI studies revealed tumour growth in 42 patients. Five subjects interrupted regular follow-up after a period of 1-3 years in which NG (four patients) or a stable residual mass (one patient) was imaged. They returned to follow-up 53, 66, 67, 90 and 96 months after surgery because of clinical signs of recurrence. Twenty-one patients underwent a second transsphenoidal surgery, six patients had surgery followed by irradiation, four patients were referred to radiation therapy and eight were started on dopamine agonist therapy. Kaplan-Meier relapse-free (tumour control) survival curve for the whole cohort shows that mean actuarial relapse-free survival was 61 ± 3·8 months. The 2-and 5-year relapse-free survival in this cohort was 78% and 48%, respectively.
Upon separate analysis and comparison between patients with or without postoperative residual mass, the following distinctions were found: Mean time for residual tumour enlargement was 27·3 ± 14 months, whereas time for detection of tumour relapse in patients with NG was 61 ± 24 months ( P < 0·0001). Mean follow-up time was similar in the two groups. Patients with residual mass after surgery were slightly older then patients with NG (56·9 ± 13 vs. 50·5 ± 17, P = 0·06). Kaplan-Meier tumour control (relapse-free) survival curves calculated separately for these two groups were also significantly different ( P < 0·0001) as depicted in Fig. 6 . Mean actuarial relapse-free survival was 42·3 ± 2·6 months for patients with residual mass and 86·4 ± 4·8 months for patients with NG. The 2-and 5-year relapse-free survival was 70% and 30%, respectively, in patients with postoperative residual mass, as opposed to 100% and 84%, respectively, in patients with NG. Fig. 5 Effect of the degree of invasion to the cavernous sinuses after surgery on tumour recurrence and on postoperative residual mass enlargement. Lane 0 denotes no invasion to the cavernous sinuses. Lanes E1, E2 and E3 denote increasing degree of invasion to cavernous sinuses. Percentages refer to patients with tumour recurrence or tumour size enlargement in each group.
Fig. 6
Actuarial recurrence-free survival in the group of patients with a normal gland (grey line) and remnant enlargement-free survival in the group of patients with residual mass (black line) after surgery (P < 0·0001).
Patients who received radiation therapy
Fourteen patients were irradiated between 1989 and 1992. A higher proportion of these patients had grade IV tumours (13 of 14, 93%) in comparison with patients that were not irradiated (65 of 109, 59·6%), P < 0·03. The frequency and degree of invasion to the cavernous sinuses before surgery was also higher and more prominent in tumours of patients who received postoperative radiation, compared with those who did not, respectively (43% vs. 20% with stages E2 or E3, P < 0·04). After surgery, 64% (9/14) of patients who received, but just 27·7% (30/108) of patients who did not receive, subsequent radiation therapy had residual suprasellar extension ( P = 0·0058). The degree of infrasellar extension did not differ between irradiated and nonirradiated patients. Tumour growth persisted in five patients despite radiation therapy. In four subjects, reduction in tumour volume was observed, and in the remaining five patients no change in tumour size was detected on MRI during the follow-up period. The rate of tumour regrowth did not differ between the irradiated subjects and the rest of this cohort.
Discussion
Treatment of NFPA has traditionally consisted of surgical excision of the tumour followed by irradiation of any residual mass. This approach is based on early reports of high recurrence rates of tumours treated by surgery alone, ranging from 12% (Ebersold et al ., 1986) to 69% (Sheline, 1974) in different series. Furthermore, good long-term tumour control rates were achieved with adjunctive postoperative radiation therapy (Ciric et al ., 1983) .
Many of these studies, however, antedate modern surgical and imaging techniques or include a large time span during which treatment changed and evolved (Tsang et al ., 1994; Breen et al ., 1998) . Interpretation of many studies is complicated by the lack of preoperative characterization of tumours by size and degree of invasiveness, unavailability of data on completeness of tumour resection and the inclusion of secreting and nonsecreting tumours in the same series (Ciric et al ., 1983) . Furthermore, almost all series were retrospective and the use of radiation therapy was arbitrary (Woolons et al ., 2000) . Because criteria for the use of radiation were not specified, true evaluation of its effects in the prevention of tumour recurrence remains difficult (Katzenelson et al ., 1993) . Our study illustrates well this type of bias in patient selection, as until 1992 only patients with larger pre-and postoperative masses were referred for radiation therapy. As a consequence, the long-term effects of this therapy on tumour control are poor in this group of more aggressive tumours, not differing from the untreated group in our series. Gittoes et al . (1998) have recently analysed the effect of radiation therapy on postoperative growth of NFPA by comparing recurrence-free survival curves from two centres in Britain, one which routinely administered radiotherapy after surgery and another which routinely did not use this treatment after transsphenoidal tumour resection. Although this was not a randomized trial, it likely avoided the selection bias usually present when the decision about administering adjunctive therapy is based on tumour size and extension or the personal beliefs and experience of the attending physicians. This study showed that radiotherapy significantly reduced the risk of tumour growth, with an actuarial 10-year progression-free survival of 93% for irradiated patients vs. 47% for patients not subjected to irradiation.
The side-effects of radiation therapy are well recognized, including hypopituitarism in about half of treated subjects, as well as an increased risk for optic nerve damage, neurological dysfunction and secondary brain tumours (Hansen & Molitch, 1998) . To prevent these complications some groups reserved radiation therapy to patients with evidence of parapituitary invasion, suprasellar extension after surgery, histological features suggesting aggressive tumour behaviour or incomplete surgical removal (Bradley et al ., 1994; Lillehei et al ., 1998; Turner et al ., 1999) . Initial follow-up reports of this selected untreated group were reassuring with low recurrence rates: 6% (Lillehei et al ., 1998) and 10% (Bradley et al ., 1994 ) 5-year recurrence rate. Further follow-up, however, revealed a less favourable prospect with just 56% recurrence-free survival at 10 years by life-table analysis (Turner et al ., 1999) . Recently, Soto-Ares et al . (2002) reported the results of MRI follow-up of 51 nonirradiated patients with NFPA, reinforcing the strategy of withholding radiation therapy from low-risk patients, provided that adequate surveillance is instituted.
In the present series, particularly after 1992, no patient received routine postoperative radiation therapy, irrespective of the surgical outcome. This gave us the opportunity to study the natural history of NFPA, and to identify subgroups of patients with distinct risks for tumour recurrence/enlargement. A similar analysis was performed by Comtois et al . (1991) in 1991. However, that study was retrospective and included many patients who were evaluated before the computed tomography (CT) era. Despite inherent limitations in accurate assessment of the presence of tumour invasion and residual tumour enlargement, this study revealed a higher incidence of recurrence in invasive tumours (33%) than in enclosed adenomas (15%; Comtois et al ., 1991) .
Our study is unique in that a large group of nonirradiated patients operated by one single surgeon was prospectively followed during a long period. This enabled us to perform a detailed evaluation of pre-and postoperative tumour characteristics predictive of poor clinical outcome, which has not been previously performed. Furthermore, the fact that a single and very experienced surgeon performed all the operations, thus providing uniform and high quality postoperative results, must be emphasized. It allows us confidently to present outcomes that are independent of different degrees of surgical expertise, as recommended and previously reported in patients with acromegaly .
In our cohort, the 5-year recurrence-free survival was 48%. Upon careful analysis, a substantial difference was found between the group of patients with postoperative residual tumours, who had a 5-year recurrence-free survival of only about 30% and patients with NG, in whom 84% remained free of disease. We were also able to identify a subgroup of patients at higher risk for postoperative residual tumour enlargement, i.e. individuals with either preoperative cavernous sinus invasion or large postsurgical suprasellar remnants. Conversely, patients in whom gross total tumour removal was achieved by surgery had a low incidence of recurrence. This information should facilitate the selection of patients in whom radiation therapy is likely necessary for tumour control, and confirms that close postoperative follow-up is an adequate primary approach in low risk patients.
